donation
To request Mental Health
Services or to access Mental
Health Crisis Services Call:
1-800-375-4357

Medical Disorders
Resources
Basic InformationLookupsLatest News
Pfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenDeadly Liver Disease Tied to Obesity Is on the RiseCDC Signs Off on Moderna, J&J Boosters, Backs Mix n' Match ShotsMoving Monoclonal Antibody Treatments for COVID From Hospital to HomeConfusion, Seizures: People Hospitalized After Taking Veterinary Drug for COVIDMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyPfizer Vaccine Booster Restores Nearly Full Protection, Company SaysTen Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune DiseaseSex of Fetus May Matter When COVID Strikes in PregnancyU.S. Has Shared 200 Million Shots With Other CountriesSalmonella Outbreak in 37 States Linked to Imported OnionsFDA Approves Moderna, J&J Booster Shots, Backs Mix n' Match VaccinesWhite House Announces COVID Vaccination Plan for Young KidsEven With Mild COVID, Obesity May Mean Worse SymptomsNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsFlu Cases Already Up 23% This Season: WalgreensDoctors Report That Kidney Grown in Pig Worked in a HumanHeartburn Meds Might Be Good for Your GumsOne Big Factor for Survival After Spinal Cord Injury: ResilienceDying Young From Heart Disease: Where You Live in the U.S. MattersFDA Expected to Allow Mix n' Match COVID VaccinesPowell's COVID Death Despite Vaccination Shows Danger to Those With Weakened Immune SystemsAHA News: Your Next Doctor's Prescription Might Be to Spend Time in NatureOut-of-Pocket Medical Bills for COVID-19 May Average $3,800 in 2021: StudyLegionnaires' Disease Outbreak Hits Long Island, N.Y.State Lotteries Didn't Help Boost Vaccination RatesFDA Panel Recommends Approval of Johnson & Johnson Booster ShotHeart Defibs in Schools Are Saving Staff Lives: StudyHorseback Riding Carries Big Risk for Serious Injury: StudyTwo-Thirds of Parents of Kids Ages 5-11 Plan to Get Them Vaccinated Against COVID: PollAnother Study Finds Pfizer, Moderna Shots Effective Against COVID VariantsLyme Disease Often Spotted at Later Stage in Black PatientsFDA Panel Supports Moderna Booster Shot for Older Adults, People at High RiskIs a Really Bad Flu Season on the Way?Climate Change Could Bring Rising Obesity RatesKids Can Carry High, Infectious Levels of COVID CoronavirusMore Than Half of COVID-19 Survivors Will Get 'Long COVID'One-Third of Americans With Arthritis Get No ExerciseDeath Threats, Trolling Common for Scientists Who Speak to Media About COVIDAHA News: The Differences and Similarities Between the Flu and COVID-19FDA Questions Strength of Johnson & Johnson's Booster Shot DataHelmets Can Saves Lives in ATV, Dirt Bike CrashesCancer Care Costs U.S. $156 Billion Per Year; Drugs a Major FactorFDA Expert Panel to Weigh Approval of Moderna, Johnson & Johnson Booster ShotsAnti-Nausea Drug May Boost Survival for Some Cancer PatientsExpert Panel Backs Off Recommendation for Aspirin to Prevent Heart TroubleAccess to Top Drugs Makes the Difference for Black Lung Cancer PatientsRisk of COVID from Grocery Store Surfaces Very Low: Study60% of Americans Will Delay or Skip Flu Shot This Year: Survey
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Trial Into Antioxidant for Parkinson's Disease Yields Disappointing Results

HealthDay News
by Cara Murez
Updated: Sep 17th 2021

new article illustration

FRIDAY, Sept. 17, 2021 (HealthDay News) – Researchers hoped to show that the natural antioxidant urate could delay Parkinson's disease progression, but a study completed at Massachusetts General Hospital dashed those expectations.

The trial enrolled nearly 300 individuals recently diagnosed with early Parkinson's disease, which affects the body's motor system. Symptoms such as tremors, stiff limbs and balance problems progress gradually, and there is no known cure.

The research team found no significant difference in the rate of disease progression for those given the metabolite inosine for two years compared to the placebo group.

Inosine raises levels of urate in the brain and blood. It has appeared neuroprotective in preclinical models.

The inosine did not prove beneficial, and those who received it also had an increased rate of kidney stones, according to the study.

"The convergence of epidemiological, biological and clinical data from past research made a compelling argument that elevating urate, the main antioxidant circulating in the blood, could protect against the oxidative damage thought to play a role in Parkinson's disease," said senior author Dr. Michael Schwarzschild, a neurologist at Mass General and a professor of neurology at Harvard Medical School.

"While our study did not rule out a protective effect of urate in Parkinson's, it clearly showed that increasing urate did not slow disease progression based on clinical assessments and serial bran scan," he added in a hospital news release.

Though it didn't provide answers to disease progression, Schwarzschild said the study was successful in other ways.

"The findings were very helpful in providing a reality check that now allows the field to move on to other therapeutic approaches," said Schwarzschild. "We also learned a lot in terms of clinical trials science for Parkinson's, and ways to conduct future studies that will increase their chance of success."

The findings were published Sept. 14 in the Journal of the American Medical Association.

More information

The Parkinson's Foundation has more on Parkinson's disease.


SOURCE: Massachusetts General Hospital-Harvard University, news release, Sept. 14, 2021